Neurosense therapeutics ltd.NRSN.US Overview

US StockHealthcare

(No presentation for NRSN)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NRSN Overall Performance

NRSN AI Analysis & Strategy

NRSN Recent Performance

-2.28%

Neurosense therapeutics ltd.

0.81%

Avg of Sector

-1.14%

S&P500

NRSN PowerScanner

NRSN Key Information

NRSN Valuation Metrics

NRSN Earnings Table

NRSN Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.